Newspatrolling.com News cum Content Syndication Portal Online
Hyderabad, India – 3 March 2025 – Neovantage Innovation Park, the largest private owner and operator of life sciences infrastructure in South Asia, marked a significant presence at BioAsia 2025, underscoring its commitment to fostering a world-class life sciences infrastructure in Telangana.
As part of its participation at BioAsia, Neovantage Innovation Park hosted a delegation from BioAsia for an exclusive site visit. The delegation consisted of governmental and industry delegates including Sh. Jayesh Ranjan, IAS, Special Chief Secretary IT&EC and Department of Commerce and Industries, Sh. Shakthi Nagappan, CEO Telangana Life Sciences , Dr. Kathrin Misera-Lang, Consul General for Germany, Ms. Amita Desai, Honorary Consul for Germany. The visit showcased Building 3600 and facilities designed to house leading biotech and life sciences companies. The park has recently welcomed several pioneering tenants, further cementing its position as a hub for scientific breakthroughs.
A key highlight of the visit was the inauguration of the Miltenyi Innovation and Technology Center, a CGT Centre of Excellence (COE). The center is the first of its kind in India for cutting-edge cell and gene therapy research and manufacturing. The launch represents a major milestone in India’s journey toward advanced biopharmaceutical innovation, reinforcing Telangana’s reputation as a leading life sciences destination. Miltenyi was represented by Dr. Boris Stoffel , CEO, Miltenyi Biotech, Ms. Priya Hingorani, Managing Director, Miltenyi Biotec India and their senior management team and employees. The inauguration was followed by tree planting ceremony in the campus.
“We are proud to contribute to the growth of India’s life sciences sector by providing world-class infrastructure tailored for biotech and pharmaceutical companies,” said Atul Bhadwaj, Business Head at Lighthouse Canton Real Estate and Head of Projects and Business Development at Neovantage Innovation Parks. “The inauguration of Miltenyi Biotec’s facility and our continued expansion demonstrate our commitment to creating an enabling environment for next-generation therapies and healthcare innovation.”
